As artificial intelligence infrastructure expands at pace, the insurance risks surrounding global data centres are growing increasingly complex and harder to manage. Large lawsuits involving data centres more than tripled from four
Merck has secured FDA approval for Lipfendra, its internally developed cholesterol-lowering drug, marking a significant milestone in cardiovascular medicine. Lipfendra, known scientifically as enlicitide, is a macrocyclic peptide that becomes the first
More
The fourth day of the National Association of Wholesaler-Distributors (NAW) v. Feldon bench trial focused on the practical administration of Oregon’s Plastic Pollution and Recycling Modernization Act (RMA). Witnesses from the Oregon
More
The Improving Seniors’ Timely Access to Care Act cleared the House Ways and Means Committee by a unanimous recorded vote of 42-0 on Wednesday, drawing widespread praise from healthcare advocates. The bipartisan
More
Consumer discretionary stocks experienced notable price movements during Friday’s trading session, drawing attention from investors tracking the sector closely. The consumer discretionary sector, which includes retailers, automakers, and leisure companies, is widely
More
Sony’s PlayStation Portal launched in 2023 to a deeply confused reception, with many buyers shocked to discover the £200 device could not actually play games independently. The Portal was originally designed purely
More
Novo Nordisk and biosimilar developer Alvotech are both contending with renewed regulatory pressure over manufacturing practices at facilities with troubled inspection histories. The U.S. Food and Drug Administration this week disclosed concerns
More
The 2026 election cycle spans 30 states, two U.S. territories, and the District of Columbia (33 attorney general offices total), featuring an unprecedented volume of structural changes driven by constitutional term limits
More
Global technology stocks suffered a severe sell-off on Friday, with chip manufacturers bearing the brunt of a sweeping downturn that rattled markets from Tokyo to New York. The Nasdaq Composite plunged 1.9
More
The FTSE 250 index has long played second fiddle to its larger counterpart, but income investors are increasingly turning their attention to its dividend potential. While the FTSE 100 dominates headlines, the
More
Novartis has secured traditional FDA approval for Fabhalta, also known as iptacopan, to slow kidney function decline in adults with primary immunoglobulin A nephropathy. The approval targets adults with IgAN who are
More